NO20092227L - Salter og krystallformer av 2-metyl-2-[4-(3-metyl-2-okso-8-konolin-3-yl-2,3-dihydro-imidazo[4,5-C]kinolin-1-yl)-fenyl]-propionitril - Google Patents
Salter og krystallformer av 2-metyl-2-[4-(3-metyl-2-okso-8-konolin-3-yl-2,3-dihydro-imidazo[4,5-C]kinolin-1-yl)-fenyl]-propionitrilInfo
- Publication number
- NO20092227L NO20092227L NO20092227A NO20092227A NO20092227L NO 20092227 L NO20092227 L NO 20092227L NO 20092227 A NO20092227 A NO 20092227A NO 20092227 A NO20092227 A NO 20092227A NO 20092227 L NO20092227 L NO 20092227L
- Authority
- NO
- Norway
- Prior art keywords
- methyl
- quinolin
- salts
- propionitrile
- imidazo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
- C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86648306P | 2006-11-20 | 2006-11-20 | |
PCT/US2007/084893 WO2008064093A2 (en) | 2006-11-20 | 2007-11-16 | Salts and crystal forms of 2-methyl-2-[4-(3-methyl-2-oxo-8-quinolin-3-yl-2,3-dihydro-imidazo[4,5-c]quinolin-1-yl)-phenyl]-propionitrile |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20092227L true NO20092227L (no) | 2009-08-17 |
Family
ID=39345299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20092227A NO20092227L (no) | 2006-11-20 | 2009-06-09 | Salter og krystallformer av 2-metyl-2-[4-(3-metyl-2-okso-8-konolin-3-yl-2,3-dihydro-imidazo[4,5-C]kinolin-1-yl)-fenyl]-propionitril |
Country Status (36)
Country | Link |
---|---|
US (2) | US8436177B2 (es) |
EP (2) | EP2364981A1 (es) |
JP (2) | JP5562033B2 (es) |
KR (3) | KR20140091718A (es) |
CN (5) | CN106045993A (es) |
AR (1) | AR064256A1 (es) |
AU (1) | AU2007323820B2 (es) |
BR (1) | BRPI0719112A2 (es) |
CA (1) | CA2669199C (es) |
CL (1) | CL2007003316A1 (es) |
CO (1) | CO6382134A2 (es) |
CR (1) | CR10757A (es) |
DO (1) | DOP2009000116A (es) |
EA (1) | EA015677B1 (es) |
EC (1) | ECSP099340A (es) |
GE (1) | GEP20125436B (es) |
GT (1) | GT200900133A (es) |
HK (1) | HK1132739A1 (es) |
HR (1) | HRP20140627T1 (es) |
IL (2) | IL198467A (es) |
JO (1) | JO2903B1 (es) |
MA (1) | MA30967B1 (es) |
MX (1) | MX2009005360A (es) |
MY (1) | MY150216A (es) |
NI (1) | NI200900091A (es) |
NO (1) | NO20092227L (es) |
NZ (1) | NZ576357A (es) |
PE (2) | PE20081780A1 (es) |
PH (1) | PH12013502100A1 (es) |
RS (1) | RS53335B (es) |
SM (1) | SMP200900041B (es) |
TN (1) | TN2009000191A1 (es) |
TW (2) | TW201402567A (es) |
UA (1) | UA98473C2 (es) |
UY (1) | UY30728A1 (es) |
WO (1) | WO2008064093A2 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2010007418A (es) | 2008-01-04 | 2010-11-12 | Intellikine Inc | Ciertas entidades quimicas, composiciones y metodos. |
US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
BRPI0909082A2 (pt) * | 2008-03-26 | 2019-02-26 | Novartis Ag | imidazoquinolinas e derivados de pirimidina como moduladores potentes de processos angiogênicos acionados por vegf |
WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
CA2760791C (en) | 2009-05-07 | 2017-06-20 | Intellikine, Inc. | Heterocyclic compounds and uses thereof |
PE20120224A1 (es) | 2009-06-04 | 2012-04-04 | Novartis Ag | Derivados de 1h-imidazo-[4,5-c]-quinolinona |
UA110697C2 (uk) | 2010-02-03 | 2016-02-10 | Сігнал Фармасьютікалз, Елелсі | ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK |
WO2011146882A1 (en) | 2010-05-21 | 2011-11-24 | Intellikine, Inc. | Chemical compounds, compositions and methods for kinase modulation |
DE102010035744A1 (de) * | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
EP2637669A4 (en) | 2010-11-10 | 2014-04-02 | Infinity Pharmaceuticals Inc | Heterocyclic compounds and their use |
EP2663309B1 (en) | 2011-01-10 | 2017-03-15 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
CA2842190A1 (en) | 2011-07-19 | 2013-01-24 | Infinity Pharmaceuticals Inc. | Heterocyclic compounds and uses thereof |
EP2734520B1 (en) | 2011-07-19 | 2016-09-14 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
RU2014111823A (ru) | 2011-08-29 | 2015-10-10 | Инфинити Фармасьютикалз, Инк. | Гетероциклические соединения и их применения |
EA201490725A1 (ru) * | 2011-09-30 | 2014-11-28 | Дана-Фарбер Кэнсер Инститьют, Инк. | Способ лечения мукоэпидермоидной карциномы |
CN103467482B (zh) | 2012-04-10 | 2017-05-10 | 上海璎黎药业有限公司 | 稠合嘧啶类化合物,其制备方法,中间体,组合物和应用 |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
MA38522A1 (fr) * | 2013-03-21 | 2017-10-31 | Novartis Ag | Thérapie de combinaison comprenant un inhibiteur de b-raf et un second inhibiteur. |
CA2909579A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and n-(3-(5-fluoro-2-(4-(2-methoxyethoxy)phenylamino)pyrimidin-4-ylamino)phenyl)acrylamide for treating cancer |
TW201527300A (zh) | 2013-04-17 | 2015-07-16 | Signal Pharm Llc | 關於1-乙基-7-(2-甲基-6-(1H-1,2,4-三唑-3-基)吡啶-3-基)-3,4-二氫吡并[2,3-b]吡-2(1H)-酮之醫藥調配物、方法、固態型式及使用方法 |
CA2908742C (en) | 2013-04-17 | 2021-06-01 | Signal Pharmaceuticals, Llc | Combination therapy comprising a tor kinase inhibitor and a cytidine analog for treating cancer |
JP6382949B2 (ja) | 2013-04-17 | 2018-08-29 | シグナル ファーマシューティカルズ,エルエルシー | 癌を治療するためのtorキナーゼ阻害剤及び5−置換キナゾリノン化合物を含む組合せ療法 |
UA119538C2 (uk) | 2013-04-17 | 2019-07-10 | Сігнал Фармасьютікалз, Елелсі | Лікування злоякісної пухлини дигідропіразинопіразинами |
TWI656875B (zh) | 2013-04-17 | 2019-04-21 | 美商標誌製藥公司 | 藉二氫吡并吡治療癌症 |
WO2014172431A1 (en) | 2013-04-17 | 2014-10-23 | Signal Pharmaceuticals, Llc | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer |
CN113831345A (zh) | 2013-05-29 | 2021-12-24 | 西格诺药品有限公司 | 二氢吡嗪并吡嗪化合物的药物组合物、其固体形式和它们的用途 |
US9745321B2 (en) | 2013-09-30 | 2017-08-29 | Shanghai Yingli Pharmaceutical Co., Ltd | Fused pyrimidine compound, intermediate, preparation method therefor, and composition and application thereof |
HUE057734T2 (hu) | 2013-10-04 | 2022-06-28 | Infinity Pharmaceuticals Inc | Heterociklusos vegyületek és alkalmazásuk |
WO2015051241A1 (en) | 2013-10-04 | 2015-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
JP6139789B2 (ja) | 2013-10-16 | 2017-05-31 | シャンハイ インリ ファーマシューティカル カンパニー リミティド | 縮合複素環化合物、その調製方法、医薬組成物及びその使用 |
CN106456628A (zh) | 2014-03-19 | 2017-02-22 | 无限药品股份有限公司 | 用于治疗PI3K‑γ介导的障碍的杂环化合物 |
WO2015160880A1 (en) | 2014-04-16 | 2015-10-22 | Signal Pharmaceuticals, Llc | SOLID FORMS COMPRISING 1-ETHYL-7-(2-METHYL-6-(1H-1,2,4-TRIAZOL-3-YL) PYRIDIN-3-YL)-3,4-DIHYDROPYRAZINO(2,3-b)PYRAZIN-2(1H)-ONE, AND A COFORMER, COMPOSITIONS AND METHODS OF USE THEREOF |
NZ714742A (en) | 2014-04-16 | 2017-04-28 | Signal Pharm Llc | Solid forms of 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one, compositions thereof and methods of their use |
WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2016054491A1 (en) | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
MX2017014776A (es) | 2015-05-20 | 2018-02-15 | Novartis Ag | Combinacion farmaceutica de everolimus con dactolisib. |
CN108349985A (zh) | 2015-09-14 | 2018-07-31 | 无限药品股份有限公司 | 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法 |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
WO2017223422A1 (en) | 2016-06-24 | 2017-12-28 | Infinity Pharmaceuticals, Inc. | Combination therapies |
AU2017363970A1 (en) | 2016-11-23 | 2019-06-20 | Novartis Ag | Methods of enhancing immune response with everolimus, dactolisib or both |
EP3641772B1 (en) | 2017-06-22 | 2023-08-02 | Celgene Corporation | Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection |
US10596165B2 (en) | 2018-02-12 | 2020-03-24 | resTORbio, Inc. | Combination therapies |
CN111187181B (zh) * | 2019-11-22 | 2023-05-05 | 吉林大学 | 一种2-(4-氨基苯基)-2-甲基丙腈化合物的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4929624A (en) | 1989-03-23 | 1990-05-29 | Minnesota Mining And Manufacturing Company | Olefinic 1H-imidazo(4,5-c)quinolin-4-amines |
US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | 1h―イミダゾピリジン誘導体 |
GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
ATE400573T1 (de) * | 2003-11-21 | 2008-07-15 | Novartis Pharma Gmbh | 1h-imidazochinolinderivate als proteinkinaseinhibitoren |
AR046845A1 (es) | 2003-11-21 | 2005-12-28 | Novartis Ag | Derivados de 1h-imidazo[4,5-c]quinolina para tratamiento de enfermedades dependientes de las proteino-quinasas |
WO2006000020A1 (en) | 2004-06-29 | 2006-01-05 | European Nickel Plc | Improved leaching of base metals |
GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
-
2007
- 2007-11-16 NZ NZ576357A patent/NZ576357A/en not_active IP Right Cessation
- 2007-11-16 RS RS20140278A patent/RS53335B/en unknown
- 2007-11-16 CN CN201610405653.7A patent/CN106045993A/zh active Pending
- 2007-11-16 CN CN201910073048.8A patent/CN109970735A/zh active Pending
- 2007-11-16 KR KR1020147014039A patent/KR20140091718A/ko not_active Application Discontinuation
- 2007-11-16 EP EP10176298A patent/EP2364981A1/en not_active Withdrawn
- 2007-11-16 WO PCT/US2007/084893 patent/WO2008064093A2/en active Application Filing
- 2007-11-16 CN CN2011103337901A patent/CN102336752A/zh active Pending
- 2007-11-16 MY MYPI20091920A patent/MY150216A/en unknown
- 2007-11-16 AU AU2007323820A patent/AU2007323820B2/en not_active Ceased
- 2007-11-16 US US12/514,976 patent/US8436177B2/en active Active
- 2007-11-16 UA UAA200905006A patent/UA98473C2/ru unknown
- 2007-11-16 MX MX2009005360A patent/MX2009005360A/es active IP Right Grant
- 2007-11-16 CN CN2012102686473A patent/CN102993202A/zh active Pending
- 2007-11-16 GE GEAP200711260A patent/GEP20125436B/en unknown
- 2007-11-16 EA EA200900638A patent/EA015677B1/ru not_active IP Right Cessation
- 2007-11-16 CN CNA2007800420773A patent/CN101541793A/zh active Pending
- 2007-11-16 KR KR1020097010203A patent/KR20090080530A/ko not_active Application Discontinuation
- 2007-11-16 KR KR1020147029446A patent/KR20140129396A/ko not_active Application Discontinuation
- 2007-11-16 AR ARP070105114A patent/AR064256A1/es unknown
- 2007-11-16 CA CA2669199A patent/CA2669199C/en not_active Expired - Fee Related
- 2007-11-16 BR BRPI0719112-0A patent/BRPI0719112A2/pt not_active IP Right Cessation
- 2007-11-16 JP JP2009537381A patent/JP5562033B2/ja not_active Expired - Fee Related
- 2007-11-16 EP EP07864492.9A patent/EP2094700B1/en active Active
- 2007-11-19 TW TW102134663A patent/TW201402567A/zh unknown
- 2007-11-19 TW TW096143742A patent/TWI417292B/zh not_active IP Right Cessation
- 2007-11-19 JO JO2007482A patent/JO2903B1/en active
- 2007-11-19 PE PE2007001607A patent/PE20081780A1/es not_active Application Discontinuation
- 2007-11-19 PE PE2011001508A patent/PE20120083A1/es not_active Application Discontinuation
- 2007-11-19 CL CL200703316A patent/CL2007003316A1/es unknown
- 2007-11-20 UY UY30728A patent/UY30728A1/es not_active Application Discontinuation
-
2009
- 2009-04-29 CR CR10757A patent/CR10757A/es unknown
- 2009-04-30 IL IL198467A patent/IL198467A/en not_active IP Right Cessation
- 2009-05-15 TN TNP2009000191A patent/TN2009000191A1/fr unknown
- 2009-05-18 GT GT200900133A patent/GT200900133A/es unknown
- 2009-05-18 NI NI200900091A patent/NI200900091A/es unknown
- 2009-05-18 CO CO09050683A patent/CO6382134A2/es active IP Right Grant
- 2009-05-18 EC EC2009009340A patent/ECSP099340A/es unknown
- 2009-05-19 DO DO2009000116A patent/DOP2009000116A/es unknown
- 2009-05-28 SM SM200900041T patent/SMP200900041B/it unknown
- 2009-06-03 MA MA31947A patent/MA30967B1/fr unknown
- 2009-06-09 NO NO20092227A patent/NO20092227L/no not_active Application Discontinuation
-
2010
- 2010-01-08 HK HK10100151.3A patent/HK1132739A1/xx not_active IP Right Cessation
-
2012
- 2012-05-17 IL IL219877A patent/IL219877A0/en unknown
-
2013
- 2013-04-04 US US13/856,458 patent/US20130289064A1/en not_active Abandoned
- 2013-05-13 JP JP2013101604A patent/JP2013173788A/ja active Pending
- 2013-10-10 PH PH12013502100A patent/PH12013502100A1/en unknown
-
2014
- 2014-07-01 HR HRP20140627TT patent/HRP20140627T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20092227L (no) | Salter og krystallformer av 2-metyl-2-[4-(3-metyl-2-okso-8-konolin-3-yl-2,3-dihydro-imidazo[4,5-C]kinolin-1-yl)-fenyl]-propionitril | |
NO20083501L (no) | Azaindoler som er anvendelige som inhibitorer for Janus-kinaser | |
NO20064584L (no) | Tetrahydropyridoindolderivater | |
NO20082090L (no) | Pyridopyrimidinoninhibitorer av P13K alfa | |
NO20073628L (no) | Pyridoner som er nyttige som inhibitorer av kinaser | |
WO2009066152A3 (en) | Haloallylamine inhibitors of ssao/vap-1 and uses therefor | |
NO20092651L (no) | Dihydropyridinderivater som er anvendelige som proteinkinaseinhibitorer | |
NO20081482L (no) | Delta- og epsilon-krystallformer for imatinibmesylat | |
NO20090595L (no) | Ny pyridazinforbindelse og anvendelse derav | |
NO20084652L (no) | Deazapuriner anvendelige som inhibitorer av januskinaser | |
NO20081844L (no) | Terapeutiske forbindelser | |
NO20064976L (no) | Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser | |
MX2010010300A (es) | Formas de sal de inhibidores del objetivo de rapamicina en mamiferos. | |
NO20082496L (no) | Pyrazinderivater | |
WO2011092469A8 (en) | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy | |
NO20072290L (no) | Organiske forbindelser. | |
NO20083250L (no) | Antibakterielle pyrrolopyridiner, pyrrolopyrimidiner og pyrroloazepiner | |
NO20073631L (no) | Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel | |
NO20090171L (no) | Substituerte aminopyrazolpyridiner og salter derav, fremgangsmate for fremstilling av slike, og farmasoytiske preparater inneholdende slike | |
UA96277C2 (en) | Benzimidazole derivatives | |
NO20070502L (no) | Azaindoler nyttige som inhibitorer av proteinkinaser | |
CL2012002887A1 (es) | Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer. | |
DK2040703T3 (da) | Derivater af 2-benzoylimidazopyridiner, fremstilling deraf og terapeutisk anvendelse deraf | |
NO20074780L (no) | Heterocyklylamidsubstituerte imidazoler | |
NO20080110L (no) | Benzimidazolderivativer som 5-HT6,5-HT24 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |